Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 28, 2026Targeted OncologyOpen Access

Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMelanie BathonMedizinische Hochschule HannoverNBNele BinderMedizinische Hochschule HannoverSWSabrina WellandMedizinische Hochschule Hannover

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows treatment patterns and outcomes evolve in hepatocellular carcinoma, indicating shifting strategies and ongoing challenges.

Key Points

  • The study aims to assess changes in treatment sequencing and survival rates for hepatocellular carcinoma over a decade.
  • Retrospective analysis of 1288 patients diagnosed with hepatocellular carcinoma between 2013-2022.
  • Patients were divided into two cohorts based on diagnosis before and after 2020, reflecting the introduction of new treatments.
  • Treatment concepts and outcomes were evaluated with a focus on liver function and tumor stage.
  • Cohort B presented at earlier tumor stages with better liver function compared to Cohort A.
  • A shift from transarterial chemoembolization towards systemic therapies was noted over time.
  • No overall survival difference was found between cohorts, and observed survival advantages for immune checkpoint inhibitors diminished after adjustment for baseline characteristics.

Cite This Study

Bathon et al. (2026) studied this question.

synapsesocial.com/papers/6a6851112845b684d16f064chttps://doi.org/10.1007/s11523-026-01239-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024 · 26,323 citations
  2. 2IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).2021 · 322 citations
  3. 3Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.2022 · 405 citations
  4. 4Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma2020 · 7,593 citations